Trial data comparison (revision 18)
Old revision·09:03, 17 Feb 2025·ConsensusConal
| Trial data comparison | |
|---|---|
Effect sizes from separate trials. Placing them side by side is not a head-to-head comparison. | |
| Rows | Major randomised trials of incretin agonists |
| Columns | Population, n, duration, comparator, endpoint, result |
| Caveats | |
| Head-to-head? | Only where the comparator column says so |
| Estimand | Stated per row where known |
| Populations | Differ substantially between trials |
| Reference tool infobox · conventions | |
The trial data comparison tabulates the principal published results of the major randomised trials of GLP-1 receptor agonists and related compounds, so that a reader arriving at one figure can see the others alongside it. Each row is attributed to its trial, arm, duration and comparator.
The table is easy to misread in one specific way, and the article exists partly to prevent it. Two figures from two trials are not a comparison of two drugs. Trial populations differ in baseline weight, glycaemic status, diabetes duration, background therapy and geography; durations differ; and the statistical estimand used to summarise a weight-change endpoint differs between publications and sometimes within a single one.[1] A larger number in this table means a larger result in that trial, and nothing more.
Where a genuine head-to-head randomised comparison exists — SURPASS-2 compared tirzepatide with semaglutide 1 mg directly — the comparator column says so, and only those rows support a statement that one agent outperformed another.[2]
The comparison
[edit]Filter by compound, trial programme or endpoint type. The bar is drawn to the magnitude of the primary result and is scaled within its endpoint type only.
References
- ^ International Council for Harmonisation, E9(R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials (2019).
- ^ Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." New England Journal of Medicine 385(6):503–515 (2021). DOI:10.1056/NEJMoa2107519. PMID 34170647.